GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Instil Bio Inc (NAS:TIL) » Definitions » FCF Yield %

TIL (Instil Bio) FCF Yield % : -40.86 (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Instil Bio FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Instil Bio's Trailing 12-Month Free Cash Flow is $-58.58 Mil, and Market Cap is $143.37 Mil. Therefore, Instil Bio's FCF Yield % for today is -40.86%.

The historical rank and industry rank for Instil Bio's FCF Yield % or its related term are showing as below:

TIL' s FCF Yield % Range Over the Past 10 Years
Min: -328.88   Med: -78.67   Max: -2.4
Current: -40.86


During the past 5 years, the highest FCF Yield % of Instil Bio was -2.40%. The lowest was -328.88%. And the median was -78.67%.

TIL's FCF Yield % is ranked worse than
72.2% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs TIL: -40.86

Instil Bio's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


Instil Bio FCF Yield % Historical Data

The historical data trend for Instil Bio's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instil Bio FCF Yield % Chart

Instil Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - -8.15 -323.07 -207.21

Instil Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -140.71 -108.47 -81.96 -63.43 -18.33

Competitive Comparison of Instil Bio's FCF Yield %

For the Biotechnology subindustry, Instil Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instil Bio's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Instil Bio's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Instil Bio's FCF Yield % falls into.



Instil Bio FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Instil Bio's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-102.692 / 49.5597942
=-207.21%

Instil Bio's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-20.133 * 4 / 439.2811764
=-18.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instil Bio FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Instil Bio FCF Yield % Related Terms

Thank you for viewing the detailed overview of Instil Bio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Instil Bio Business Description

Traded in Other Exchanges
N/A
Address
3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FR?, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Executives
Timothy L. Moore officer: Chief Operating Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Sumita Ray officer: Chief Legal and Admin Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jack Nielsen director, 10 percent owner C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Mcgaughy R Kent Jr director 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Curative Ventures V Llc 10 percent owner 3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219
Bronson Crouch director, 10 percent owner, officer: CEO and Chairman C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vivo Capital Ix, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Sandeep Laumas officer: CFO and CBO 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Gwendolyn Binder director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Zachary Roberts officer: Chief Medical Officer C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
George Matcham director C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vijay Chiruvolu officer: Chief Technical Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037

Instil Bio Headlines

From GuruFocus